Oxaloacetate

Oxaloacetate (OAA) is a key intermediate in the citric acid cycle (Krebs cycle) that plays a central role in cellular energy metabolism. It has been investigated for its potential to enhance mitochondrial function, reduce neuroinflammation, and improve metabolic health. Research suggests it may benefit conditions involving energy deficits, including chronic fatigue, neurodegenerative diseases, and aging.

Overview

Oxaloacetate (OAA) is a four-carbon dicarboxylic acid that occupies a uniquely central position in cellular metabolism, serving as both a tricarboxylic acid (TCA) cycle intermediate and the entry point for gluconeogenesis. In the TCA cycle, OAA condenses with acetyl-CoA (via citrate synthase) to form citrate, effectively gating the rate of oxidative metabolism. OAA is also the product of pyruvate carboxylation, connecting glycolysis to both the TCA cycle and gluconeogenic pathways. As a supplement, stabilized oxaloacetate (typically as the thermally stable anhydrous or enol-oxaloacetate form) has attracted significant interest as a caloric restriction (CR) mimetic — a compound that replicates the metabolic and longevity-associated signaling of caloric restriction without actual caloric reduction.

The caloric restriction mimetic properties of oxaloacetate are mediated primarily through its effects on the cytoplasmic NAD+/NADH ratio. OAA is reduced to malate by cytoplasmic malate dehydrogenase, consuming NADH and increasing the NAD+/NADH ratio — the same metabolic shift produced by caloric restriction. Elevated NAD+ activates sirtuins (particularly SIRT1 and SIRT3), AMPK, and PGC-1alpha, triggering downstream effects including enhanced mitochondrial biogenesis, improved autophagy, reduced mTOR signaling, and anti-inflammatory gene expression programs. In C. elegans studies, OAA supplementation extended lifespan by up to 25%, and in mouse models, it demonstrated neuroprotective effects in Alzheimer's disease by reducing neuroinflammation and glutamate excitotoxicity — OAA can transaminate with glutamate (via aspartate aminotransferase) to form aspartate, effectively functioning as a glutamate scavenger that may protect against excitotoxic neuronal damage.

Supplemental oxaloacetate is typically dosed at 100–200 mg daily in its thermally stabilized form. It is often combined with NMN or NR for complementary NAD+ elevation through both salvage pathway supplementation and NADH consumption, with resveratrol for sirtuin activation, and with berberine or metformin for AMPK-mediated metabolic optimization. Clinical data remains limited, with a small human trial showing reduced glutamate levels in glioblastoma patients and ongoing investigation in neurodegenerative conditions. Side effects are generally mild and may include transient gastrointestinal discomfort. Oxaloacetate represents a mechanistically compelling approach to CR mimicry, though human clinical evidence is still in early stages.

Mechanism of Action

Oxaloacetate (OAA) is a four-carbon dicarboxylic acid that serves as a critical intermediate in the tricarboxylic acid (TCA) cycle, where it condenses with acetyl-CoA via citrate synthase to form citrate, initiating each turn of the cycle. OAA is also the product of malate oxidation by malate dehydrogenase using NAD+ as a cofactor. This reaction links OAA directly to the cellular NAD+/NADH ratio, and supplemental OAA has been shown to increase the NAD+/NADH ratio, mimicking the metabolic state induced by caloric restriction and activating AMPK and sirtuin pathways.

A particularly notable mechanism is OAA's ability to lower brain glutamate levels through peripheral glutamate scavenging. In the blood, OAA undergoes transamination with glutamate via glutamate-oxaloacetate transaminase (GOT/aspartate aminotransferase), converting glutamate to aspartate and OAA to alpha-ketoglutarate. This creates a concentration gradient that draws excess glutamate out of the brain across the blood-brain barrier, providing neuroprotection against excitotoxicity without directly crossing into the CNS.

OAA also serves as a substrate for phosphoenolpyruvate carboxykinase (PEPCK) in gluconeogenesis, converting to phosphoenolpyruvate for glucose production. It participates in the malate-aspartate shuttle, transferring reducing equivalents from the cytosol into mitochondria. Through its roles in amino acid transamination, OAA connects to the urea cycle and amino acid synthesis pathways, making it a metabolic hub linking energy production, nitrogen metabolism, and neuroprotection.

Reconstitution Calculator

Research

Safety Profile

Oxaloacetate is generally considered safe at recommended doses, with mild gastrointestinal discomfort being the most commonly reported side effect. It may affect blood glucose levels and should be used with caution by individuals with diabetes or hypoglycemia. Long-term human safety studies are limited, and it should be avoided during pregnancy and breastfeeding.

Pharmacokinetic Profile